"Website is under heavy load" so can't look at specifics. But judging by another NYT article[1], it sounds like there isn't as much cause for suspicion as I wou

"Website is under heavy load" so can't look at specifics. But judging by another NYT article[1], it sounds like there isn't as much cause for suspicion as I would have originally thought. This article singles out the Chief of Cardiology at Newark Beth Israel, citing he received $270,000. It's a lot, but considering how well compensated he likely is already I'd hardly consider him bought. And he's being paid for an undefined number of speaking/consulting engagements which may make that number even less noteworthy. For the most part, this seems like a great initiative for adding transparency but ultimately highlights a non-issue (assuming further analysis doesn't change the story). [1] http://www.nytimes.com/2014/09/30/upshot/what-were-learning-about-drug-company-payments-to-doctors.html?_r=0&abt=0002&abg=1 http://www.nytimes.com/2014/09/30/upshot/what-were-learning-...